RxDoctor Payments Data

Preethi Pirlamarla, MD

Advanced Heart Failure and Transplant Cardiology · Seattle, WANPI 1043592454

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $11,644 of the $14,154 with a category attached, or 82.3%. 21 manufacturers reported payments, led by Abbott at 46.2% of the total.

$14,154in general payments, 2019–2025

Across 176 payments — averaging $80.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Cvrx, Inc.$2K
  • Bayer$2K
  • AstraZeneca$783
  • Abiomed$639
  • Boehringer Ingelheim$633
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$2,41617%
  • Food & beverage$11,64482%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,154 in reported general payments places this provider in the 70th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

See all advanced heart failure and transplant cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$55,973
Medicare patients
110
Services billed
522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis23$878,515
EntrestoSacubitril/Valsartan76$86,648
JardianceEmpagliflozin78$83,286
EliquisApixaban47$45,922
FarxigaDapagliflozin Propanediol16$20,302
Dapsone12$1,309
Torsemide35$878
Carvedilol26$747
Atorvastatin Calcium30$730
Metoprolol Succinate43$726
Spironolactone72$709
Amlodipine Besylate16$340
Losartan Potassium26$283
Pravastatin Sodium24$274
Rosuvastatin Calcium14$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$53$924,43770 claims
NovartisEntresto$100$86,64876 claims
Boehringer IngelheimJardiance$633$83,28678 claims
AstraZenecaFarxiga$783$20,30216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

Other advanced heart failure and transplant cardiology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →